Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabis for Tolerability in Glioblastoma Patients Receiving Chemoradiation
NCT03246113Phase 1Terminated
- Sponsor
- New York State Psychiatric Institute
- Start
- Mar 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cannabis in glioblastoma (GBM), sponsored by New York State Psychiatric Institute. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 6 weeks. Started Mar 2018; status: terminated.
02
Drugs
cannabis
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03246113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03246113.